The resulting 124 I-evuzamitide (previously known as AT-01) has been shown to detect amyloidosis in organs like the heart, ...

About NEXICART-2 NEXICART-2 (NCT06097832) is an ongoing multi-site U.S. Phase 1/2 clinical trial of sterically-optimized CAR-T NXC-201 in relapsed/refractory AL Amyloidosis, with a registrational ...

Oral presentation Sunday, December 7, at ASH 2025 - LOS ANGELES, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. ("ImmixBio", "Company", "We" or "Us" or "IMMX"), the global leader in relapsed/ ...

A hidden atrial dysfunction may raise stroke risk in people with transthyretin amyloid cardiomyopathy (ATTR-CM); however, a ...

A hidden atrial dysfunction may raise stroke risk in people with transthyretin amyloid cardiomyopathy (ATTR-CM); however, a noninvasive assessment tool may help identify those at increased risk, ...

Systemic light chain (AL) amyloidosis is a rare and life-threatening disorder characterized by the deposition of misfolded immunoglobulin light chains as insoluble amyloid fibrils in various tissues ...

Intellia Therapeutics also has fans on Wall Street. The company's current average price target of $32.3 (according to Yahoo!

At age 76, I was diagnosed with sinus node dysfunction last year after several episodes of what I’d call being “spaced out” ...

At age 76, I was diagnosed with sinus node dysfunction last year after several episodes of what I’d call being “spaced out” ...

INDICATION Attruby is a transthyretin stabilizer indicated for the treatment of the cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce ...

— G.W.T.Dear G.W.T.: The sinus of the heart has nothing to do with your nose as you might guess; it's a structure in the right atrium where blood flows into the heart from the venae cavae. It contains ...

Intellia Therapeutics, Inc. is rated Hold due to uncertainty from dosing pause in its MAGNITUDE program for ATTR. Learn more ...